Dr. Christopher Streib, MD
Claim this profileM Health Fairview University of Minnesota Medical Center Hospital,
Studies Stroke
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Christopher Streib, MD is currently running
Recombinant Factor VIIa
for Hemorrhagic Stroke
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
Recruiting1 award Phase 32 criteria
rFVIIa
for Hemorrhagic Stroke
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
Recruiting1 award Phase 34 criteria
More about Christopher Streib, MD
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christopher Streib, MD has experience with
- Placebo
- Recombinant Activated Factor VII (rFVIIa)
- Recombinant Factor VIIa
Breakdown of trials Christopher Streib, MD has run
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher Streib, MD specialize in?
Christopher Streib, MD focuses on Stroke and other conditions. In particular, much of their work with Stroke has involved treating patients, or patients who are undergoing treatment.
Is Christopher Streib, MD currently recruiting for clinical trials?
Yes, Christopher Streib, MD is currently recruiting for 2 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Christopher Streib, MD has studied deeply?
Yes, Christopher Streib, MD has studied treatments such as Placebo, Recombinant Activated Factor VII (rFVIIa), Recombinant Factor VIIa.
What is the best way to schedule an appointment with Christopher Streib, MD?
Apply for one of the trials that Christopher Streib, MD is conducting.
What is the office address of Christopher Streib, MD?
The office of Christopher Streib, MD is located at: M Health Fairview University of Minnesota Medical Center Hospital,, Minneapolis, Minnesota 55455 United States. This is the address for their practice at the M Health Fairview University of Minnesota Medical Center Hospital,.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.